Skip to main content

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2347${count})

  • MJFF Research Grant, 2013
    LRRK2 PET Tracer Development

    Promising Outcomes of Original Grant:
    With our initial grant from MJFF, we focused on designing and synthesizing chemical matter with physico-chemical properties such that it could travel into the...

  • Target Validation, 2013
    Effects of IL-10 on Neurodegeneration in Mutant Alpha-Synuclein Transgenic Models

    Objective/Rationale:             
    One of the hallmark pathologies in the brains of patients with Parkinson’s disease (PD) is an inflammatory response. We will test whether the cytokine interleukin-10...

  • MJFF Research Grant, 2013
    Development of G2019S Selective LRRK2 Inhibitors for the Treatment of Parkinson’s Disease

    Objective/Rationale:             
    The LRRK2 kinase has been implicated as a potential therapeutic target for the treatment of Parkinson’s disease (PD). The goal of this project is to make experimental...

  • Rapid Response Innovation Awards, 2013
    Evaluation of Targeted Plasticity Therapy as a Treatment for Motor Dysfunction in Parkinson’s Disease

    Objective/Rationale:             

    Deterioration of motor function is a debilitating symptom of Parkinson’s disease (PD). We have recently developed a novel method that utilizes stimulation of the...

  • MJFF Research Grant, 2013
    Specific Modulation of Tau Oligomers by Passive Immunotherapy in a Parkinson's Disease Model

    Objective/Rationale: 
    The accumulation of tau protein is an important pathogenic factor in Parkinson’s disease (PD) and other neurodegenerative disorders. Our recent findings from pre-clinical models...

  • LRRK2 Challenge, 2013
    In Vivo Rescue of Dopamine Release Deficits via Kinase Inhibition in LRRK2 Mutant Mice

    Objective/Rationale:             
    Abnormal kinase activity is thought to be responsible for the pathogenic effects of LRRK2 in parkinsonian patients and many lines of evidence point towards a role of...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.